MIP 1095 I-131Alternative Names: 1095; 123I-MIP-1095; [131I] MIP-1095; I131-MIP-1095; MIP-1095; MIP-1095 I123; MIP-1095 I131
Latest Information Update: 20 Feb 2017
At a glance
- Originator Molecular Insight Pharmaceuticals
- Developer Progenics Pharmaceuticals
- Class Imaging agents; Radiopharmaceuticals; Small molecules
- Mechanism of Action Glutamate carboxypeptidase II inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer